Of note, ERα polyubiquitination-mediated degradation is exploited by selective endocrine therapies acting as SERDs, such as fulvestrant, and new oral molecules that are being investigated in HR+/HER2− BC patients with tumors that are refractory to standard ETs (Figure 1) [62]. Here, ERBB2 is linked to breast cancer.